Novartis under the clinical trials reported for the production/development of cathepsin K inhibitor (named as AAE581), which was implied for the treatment of rheumatoid arthritis and osteoporosis (in 2003, http://www.novartis.com). Here, CTSK is linked to osteoporosis.